Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
Johnson and Johnson
McKesson

Last Updated: October 2, 2022

CLINICAL TRIALS PROFILE FOR HENAGLIFLOZIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Clinical Trials for Henagliflozin

Trial ID Title Status Sponsor Phase Summary
NCT02354027 ↗ The Drug-drug Interaction of SHR3824 and Metformin Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and a single oral dose of metformin in healthy adult volunteers.
NCT02356224 ↗ The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this single-dose study the investigators evaluated the safety, tolerablity and PK/PD profiles of SHR3824 in healthy subjects.
NCT02361138 ↗ The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers Completed Jiangsu HengRui Medicine Co., Ltd. Phase 1 SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in healthy subjects.
NCT02500485 ↗ The Drug-drug Interaction of SHR3824 and SP2086 Unknown status Jiangsu HengRui Medicine Co., Ltd. Phase 1 The purpose of the study is to investigate the potential interaction between multiple oral doses of SHR3824 and multiple oral doses of SP2086 in healthy adult volunteers.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Henagliflozin

Condition Name

Condition Name for
Intervention Trials
Type 2 Diabetes 5
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Diabetes Mellitus, Type 2 2
Atrial Fibrillation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Henagliflozin

Trials by Country

Trials by Country for
Location Trials
China 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Henagliflozin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 3
Unknown status 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Henagliflozin

Sponsor Name

Sponsor Name for
Sponsor Trials
Jiangsu HengRui Medicine Co., Ltd. 5
Beijing Anzhen Hospital 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 5
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
AstraZeneca
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.